Literature DB >> 3013487

The role of cardiac beta-1 receptors in the hemodynamic response to a beta-2 agonist.

M H Strauss, R A Reeves, D L Smith, F H Leenen.   

Abstract

The role of beta 1-receptors in the hemodynamic response to beta 2-stimulation was assessed in seven healthy subjects by infusion of the selective beta 2-agonist terbutaline both with and without selective beta 1-blockade by atenolol (50 mg). Infusion of terbutaline increased heart rate (+28 bpm) and indices of left ventricular (LV) performance associated with a marked decrease in LV end-systolic wall stress. The LV end-diastolic dimension remained unchanged despite the tachycardia, suggesting that venous return had increased. Systolic blood pressure increased, whereas total peripheral resistance and diastolic blood pressure decreased. Atenolol pretreatment caused the hemodynamic changes expected of beta 1-blockade but did not blunt the effects of terbutaline on heart rate, peripheral resistance, or venous return. Increases after terbutaline in LV performance and systolic blood pressure were significantly blunted by atenolol. Stimulation of beta 1-receptors therefore appears to play no role in the chronotropic and only a moderate role in the inotropic response after infusion of a beta 2-agonist. Alternative mechanisms for the cardiac changes with terbutaline include (1) withdrawal of vagal tone, (2) decrease in afterload, and (3) stimulation of cardiac beta 2-receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013487     DOI: 10.1038/clpt.1986.146

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.

Authors:  M Scheinin; M Koulu; E Laurikainen; H Allonen
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Effects of atenolol vs diltiazem on the haemodynamic effects of an inhaled beta 2-adrenoceptor agonist.

Authors:  K R Chapman; B M Galko; D L Smith; F H Leenen
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

7.  Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

Authors:  J Crane; C Burgess; R Beasley
Journal:  Thorax       Date:  1989-02       Impact factor: 9.139

8.  Cardiac beta 2-adrenoceptors and the inotropic response to exercise in man.

Authors:  C Nyarko-Adomfeh
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

9.  The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

10.  The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.

Authors:  A Flatt; J Crane; G Purdie; T Kwong; R Beasley; C Burgess
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.